← Back
Data updated: Jun 28, 2026
SEBELA WOMENS HLTH
Pharma Pharmaceuticals
SEBELA WOMENS HLTH is a pharmaceutical company with 1 FDA-approved products.
2025
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules
SEBELA WOMENS HLTH's Key Drugs
SEBELA WOMENS HLTH's core commercial portfolio centers on MIUDELLA — its most strategically important drugs approved in the last 15 years.
SEBELA WOMENS HLTH's Recent FDA Approvals
SEBELA WOMENS HLTH secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SEBELA WOMENS HLTH's Therapeutic Areas
Disease areas where SEBELA WOMENS HLTH has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
SEBELA WOMENS HLTH Pipeline Snapshot
Active clinical trials for SEBELA WOMENS HLTH across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MIUDELLA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-02-24
- Latest
- 2025-10-01
- Applications
- 1